Breaking barriers in brain cancer—NeOnc is changing how we treat the brain, for good. 

A trailblazing biotech company, NeOnc Technologies, is leading a paradigm shift in brain cancer treatment. Backed by over 176 patents and partnerships with USC and Cleveland Clinic, NeOnc is pioneering a non-invasive, 

intranasal drug delivery platform that safely bypasses the blood-brain barrier—an obstacle that has long hindered effective neuro-oncology care. As the first biotech company licensed by the USC Stevens Center to go public, NeOnc isn’t just advancing medicine—they’re redefining it. Learn how this groundbreaking science is creating new hope for patients, clinicians, and families alike.